Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Emerging therapeutic strategies in breast cancer (Oct 2026)
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles
  • Search Articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Pathobiont-triggered induction of goblet cell response drives regional susceptibility to inflammatory bowel disease
Paige N. Spencer, Monica E. Brown, Erin P. Smith, Jiawei Wang, William Kim, Luisella Spiga, Naila Tasneem, Alan J. Simmons, Taewoo Kim, Yilin Yang, Yanwen Xu, Lin Zheng, James Ro, Harsimran Kaur, Seung Woo Kang, Matthew D. Helou, Mason A. Lee, Deronisha Arceneaux, Katherine D. Mueller, Ozge S. Kuddar, Mariah H. Harned, Jing Li, Amrita Banerjee, Nicholas O. Markham, Keith T. Wilson, Lori A. Coburn, Jeremy A. Goettel, Qi Liu, M. Kay Washington, Raphael H. Valdivia, Wenhan Zhu, Ken S. Lau
Paige N. Spencer, Monica E. Brown, Erin P. Smith, Jiawei Wang, William Kim, Luisella Spiga, Naila Tasneem, Alan J. Simmons, Taewoo Kim, Yilin Yang, Yanwen Xu, Lin Zheng, James Ro, Harsimran Kaur, Seung Woo Kang, Matthew D. Helou, Mason A. Lee, Deronisha Arceneaux, Katherine D. Mueller, Ozge S. Kuddar, Mariah H. Harned, Jing Li, Amrita Banerjee, Nicholas O. Markham, Keith T. Wilson, Lori A. Coburn, Jeremy A. Goettel, Qi Liu, M. Kay Washington, Raphael H. Valdivia, Wenhan Zhu, Ken S. Lau
View: Text | PDF
Research Article Cell biology Gastroenterology Inflammation

Pathobiont-triggered induction of goblet cell response drives regional susceptibility to inflammatory bowel disease

  • Text
  • PDF
Abstract

The gastrointestinal tract varies in structure and function by region, yet the drivers of region-specific inflammatory disease remain elusive. Here, a TNF-overexpressing murine model (TnfΔARE/+) of Crohn’s disease (CD) was used to investigate how pathobionts interact with host immune susceptibilities to drive region-specific disease. We identified the pathobiont Chlamydia muridarum, an intracellular bacterium and murine counterpart to the human sexually transmitted C. trachomatis, as a necessary and sufficient trigger for disease manifestation in the proximal/ascending colon, a common site of CD. In genetically susceptible hosts, pathobiont-triggered proximal colonic inflammation is driven by goblet cell responses, including tryptophan metabolism via indoleamine 2,3-dioxygenase 1 (IDO1). Our findings translate to human disease, where we demonstrate upregulation of epithelia-derived IDO1 in actively inflamed ascending colon specimens, but not actively inflamed terminal ileum specimens, of patients with CD. Our findings mechanistically reveal how genetic and microbial factors drive the manifestation of disease in a region-specific manner and provide a unique model to study CD specific to the ascending colon.

Authors

Paige N. Spencer, Monica E. Brown, Erin P. Smith, Jiawei Wang, William Kim, Luisella Spiga, Naila Tasneem, Alan J. Simmons, Taewoo Kim, Yilin Yang, Yanwen Xu, Lin Zheng, James Ro, Harsimran Kaur, Seung Woo Kang, Matthew D. Helou, Mason A. Lee, Deronisha Arceneaux, Katherine D. Mueller, Ozge S. Kuddar, Mariah H. Harned, Jing Li, Amrita Banerjee, Nicholas O. Markham, Keith T. Wilson, Lori A. Coburn, Jeremy A. Goettel, Qi Liu, M. Kay Washington, Raphael H. Valdivia, Wenhan Zhu, Ken S. Lau

×

Figure 3

C. muridarum is necessary and sufficient to drive PC inflammation in the TnfΔARE/+ model.

Options: View larger image (or click on image) Download as PowerPoint

C. muridarum is necessary and sufficient to drive PC inflammation in th...
(A) Doxycycline experiment scheme for B–I, age-matched at 11–12 weeks at harvest. N = 4 mice per condition for B–F. (B) Fecal testing for C. muridarum at different time points. (C and D) Representative IF of Chlamydia MOMP and nuclei (C) and H&E-stained PC sections (D) from the doxycycline experiment. (E) Colitis scores of samples from D. (F) Colitis subscores that comprise E. (G) Eubacterial shotgun metagenomic data of PC luminal contents of mice treated with doxycycline (N = 4) or vehicle (N = 3), represented as relative abundance of mapped phyla for individual TnfΔARE/+ mice of mixed ages (11–23 weeks of age) across 7 cages. (H) Data from G with reads specifically mapped to C. muridarum species. (I) Data from G plotted. (J) CM001-GFP experimental scheme for K–R, age-matched at 16–20 weeks at tissue harvest. (K) Fecal testing for C. muridarum in TnfΔARE/+ mice from the CM001-GFP experiment. N = 4 mice per condition. (L) Body weight change from the CM001-GFP experiment. N = 10 mice per condition. (M) Colitis scores from the CM001-GFP experiment. N = 5 each condition. (N) H&E-stained PC sections from the CM001-GFP experiment. N = 10 mice per condition. (O) Representative IF images with insets of MOMP and endogenous GFP from CM001-GFP on PC sections. N = 5 mice per condition. Original magnification, ×20. (P) Eubacterial shotgun metagenomic data of PC luminal contents from TnfΔARE/+ mice in CM001-GFP-inoculated (N = 5) or sham (N = 4) conditions across 4 cages. (Q and R) Same analyses as in H and I but with data from P. (S) Shared enriched species from eubacterial shotgun metagenomic data analyses in Supplemental Figure 4, G–J, L, and M. All scale bars: 200 μm. Data are shown as the mean ± SEM in quantifications. Statistical significance was determined using unpaired 2-tailed t tests (E, H, L, M, and Q) or multiple unpaired 2-tailed t tests with FDR of 1% (F, I, and R). *P < 0.05, ***P < 0.001, ****P < 0.0001. See also Supplemental Figures 3 and 4, Supplemental Tables 2 and 3, and Supplemental Unedited blot and gel images.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts